

AMENDMENTS TO THE CLAIMS:

Please cancel claims 35, 39, 42 and 45.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-31 (**Canceled**)

32. (**Previously presented**) A pharmaceutical composition comprising

- a) anti-Vpr monoclonal antibodies; and
- b) a pharmaceutically acceptable carrier.

33. (**Previously presented**) A method of treating an individual exposed to HIV by administering an effective amount of anti-Vpr antibodies.

34. (**Previously presented**) A method of treating an individual who has been infected with HIV comprising the step of administering to said individual a therapeutically effective amount of anti-Vpr antibodies.

35. (**Canceled**)

36. (**Previously presented**) The pharmaceutical composition of claim 32 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

37. (**Previously presented**) A pharmaceutical composition comprising:

- a) anti-Vpr antibodies that inhibit Vpr enhancement of HIV replication; and
- b) a pharmaceutically acceptable carrier;

wherein the anti-Vpr antibodies are present in an amount effective to inhibit HIV replication in an HIV infected individual.

38. (**Previously presented**) The pharmaceutical composition of claim 37 wherein the anti-Vpr antibodies are monoclonal antibodies.

39. (Canceled)

40. (Previously presented) The pharmaceutical composition of claim 37 wherein the composition is a sterile composition and the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

41. (Previously presented) The method of claim 33 wherein the anti-Vpr antibodies are monoclonal antibodies.

42. (Canceled)

43. (Previously presented) The method of claim 33 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

44. (Previously presented) The method of claim 34 wherein the anti-Vpr antibodies are monoclonal antibodies.

45. (Canceled)

46. (Previously presented) The method of claim 34 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.